Reducing cutaneous scar formation and treating skin conditions
US-2015065431-A1 · Mar 5, 2015 · US
Epithelial ion channel (enac) blockers to treat psoriasis
US2017182040A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017182040-A1 |
| Application number | US-201515304999-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 1, 2015 |
| Priority date | May 2, 2014 |
| Publication date | Jun 29, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of treatment for psoriasis, and compositions for use in such methods are provided. An effective dose of an epithelial ion channel (ENAC) blocker is administered to an individual suffering from psoriasis. ENAC blockers, including without limitation Benzamil, can reduce thickened cutaneous psoriatic plaques.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating psoriasis in a subject, the method comprising: administering to the subject an effective dose of an epithelial ion channel (ENAC) blocker for duration and periodicity sufficient to reduce the symptoms of psoriasis. 2 . The method of claim 1 , wherein the ENAC blocker is amiloride or a derivative thereof. 3 . The method of claim 2 , wherein the ENAC blocker is benzyl amiloride. 4 . The method of claim 1 , wherein the administration is systemic. 5 . The method of claim 1 , wherein the administration is topical. 6 . The method of claim 1 , wherein dose is administered to the subject upon a flare of psoriasis. 7 . The method of claim 1 , wherein the psoriasis is chronic psoriasis. 8 . The method of claim 1 , wherein the psoriasis is plaque psoriasis. 9 . A composition in a unit dose formulation of an epithelial ion channel (ENAC) suitable for use in the methods of any one of claims 1 - 8 . 10 . The composition of claim 9 , further comprising a second therapeutic agent for treatment of psoriasis. 11 . The composition of claim 9 , wherein the formulation is suitable for topical use. 12 . The composition of claim 9 , wherein the formulation is suitable for systemic administration.
Assignees
Inventors
Classifications
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
- A61K31/4965Primary
Non-condensed pyrazines · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017182040A1 cover?
- Methods of treatment for psoriasis, and compositions for use in such methods are provided. An effective dose of an epithelial ion channel (ENAC) blocker is administered to an individual suffering from psoriasis. ENAC blockers, including without limitation Benzamil, can reduce thickened cutaneous psoriatic plaques.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4965. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jun 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).